Innoviva (INVA)

Executive Summary

Innoviva, Inc. (NASDAQ: INVA) operates a hybrid business model that combines stable royalty revenues from partnered respiratory medicines with strategic investments in a pipeline of novel therapeutics. The company's royalty stream, primarily from drugs like Anoro and Breo, provides predictable cash flow that funds its specialty therapeutics subsidiary. This subsidiary focuses on high-potential programs in oncology and infectious diseases, including sulbactam-durlobactam for Acinetobacter baumannii infections (Phase 1) and eravacycline for complicated intra-abdominal infections (Phase 2). Additionally, Innoviva has an approved product, angiotensin II for vasodilatory shock, and a Phase 2 program in non-tuberculous mycobacterial (NTM) pulmonary disease. The company's diversified approach mitigates pipeline risk while offering upside from clinical-stage assets. With a market capitalization of approximately $1.7 billion and no debt, Innoviva is well-positioned to advance its pipeline organically or through business development.

Upcoming Catalysts (preview)

• TBDPhase 2 data readout for eravacycline in complicated intra-abdominal infections40% success
• TBDPhase 1 data readout for sulbactam-durlobactam in Acinetobacter baumannii infections30% success
• Q1 2027Phase 2 trial initiation for sulbactam-durlobactam combination in NTM pulmonary disease70% success